Ethyl butyrate

Ethyl Butyrate: Recent Market Intelligence Report

I. Market Quotation Dynamics (July 10–14, 2026)
1. Price Fluctuation Range
- According to data monitored by Shengyishe (Business Society), the benchmark price of ethyl butyrate exhibited narrow-range volatility from July 10–14, with mainstream quotations in the East China region ranging between RMB 12,500–13,200 per metric ton—a rise of approximately 2.3% compared to the June average.
- Quotations in Henan Province remained stable at RMB 12,800 per metric ton; in contrast, Shandong Province saw slightly lower quotations at RMB 12,600 per metric ton, primarily due to regional logistics cost differentials.

2. Regional Price Spread Analysis
- The price differential between East China and South China widened to RMB 300–500 per metric ton, driven mainly by robust demand for pharmaceutical-grade ethyl butyrate in East China, resulting in a premium for high-end products.
- In the Pearl River Delta region, intense competition among industrial-grade producers has pressured pricing toward cost parity (approximately RMB 12,200 per metric ton), sustained by economies of scale.

II. Supply-Demand Structure Analysis
1. Supply Side
- Capacity Distribution: Domestic ethyl butyrate production capacity is concentrated in Henan, Shandong, and Jiangsu provinces. Leading enterprises—including Weishi County Flavor Factory (Henan) and Henan Xiangduobao Flavor Co., Ltd.—account for over 60% of total national capacity.
- Operating Rate: Industry-wide average operating rate reached ~75% in July, up 5 percentage points month-on-month, primarily driven by increased demand from the baijiu (Chinese distilled spirit) brewing industry entering its peak production season.
- Inventory Levels: Top-tier enterprises reduced inventory turnover days to 28 days, enhancing supply chain resilience. However, SMEs face mounting pressure to exit the market due to rising environmental compliance costs.

2. Demand Side
- Traditional Applications: Baijiu brewing and food processing collectively account for over 70% of total demand. Notably, baijiu industry procurement volume increased 12% month-on-month, fueled by heightened summer consumption.
- Emerging Applications: Demand from organic synthesis—especially for specialty polymers such as polyhydroxyalkanoates (PHA)—has grown to 15% of total demand, indicating strong long-term growth potential. Pharmaceutical-grade demand remains structurally robust, supported by ongoing optimization of advanced drug manufacturing processes.

III. Cost & Profitability Analysis
1. Raw Material Costs
- Primary feedstocks—n-butyric acid and ethanol—exhibited offsetting price trends in July: n-butyric acid prices rose ~3% MoM due to volatility in upstream acrylic acid markets, while ethanol prices fell ~2% MoM amid expectations of abundant corn harvests. Consequently, overall raw material cost changes were modest.
- Enterprises in Henan Province have adopted hedging strategies to lock in raw material costs, sustaining gross margins within the 18–20% range.

2. Profitability
- Pharmaceutical-grade ethyl butyrate—requiring ≥99.5% purity—commands significantly higher value-added, achieving gross margins of 25–30%. By contrast, industrial-grade products yield margins of only 15–18%, compressed by intensifying competitive pressure.

IV. Correlated Product Market Linkages
1. Substitutes
- Ethyl 2-methylbutyrate (a structural analog) maintained stable quotations of RMB 14,500–15,200 per metric ton—approximately 15% premium over ethyl butyrate—but limited substitutability persists due to distinct olfactory profiles.
- Butyl acetate (a functional substitute) averaged RMB 6,500 per metric ton in July—offering substantial price advantage—but cannot replace ethyl butyrate in premium fragrance applications.

2. Upstream-Downstream Linkages
- Upstream acrylic acid prices rose 5% MoM amid tightening environmental production restrictions, indirectly elevating n-butyric acid costs. However, ethyl butyrate producers mitigated part of this pressure through process optimization.
- Downstream baijiu manufacturers accelerated inventory turnover, increasing procurement volume by 10% YoY in July—providing solid demand support.

V. Technology Drivers & Policy Impacts
1. Technological Upgrades
- Biocatalytic (enzyme-based) synthesis is progressively replacing conventional chemical synthesis, reducing production costs by 15–20% while substantially lowering waste emissions—aligning with China’s “Dual Carbon” (carbon peak & neutrality) policy objectives.
- Through industry-university-research collaboration, leading firms have shortened technology commercialization cycles to 14 months and achieved chiral isomer purity exceeding 99.9%, further reinforcing the premium positioning of pharmaceutical-grade products.

2. Environmental Regulations
- Implementation of a digital, full-lifecycle regulatory system for hazardous chemicals has internalized environmental compliance costs; ESG ratings have become critical determinants for corporate financing.
- Solvent recovery rates have improved to 99.5%, cutting per-unit carbon emissions by 32.1%—meeting stringent international standards including the EU’s Carbon Border Adjustment Mechanism (CBAM)—thus facilitating export growth.

VI. Price Forecast & Risk-Opportunity Assessment
1. Short-Term Outlook (Q3 2026)
- Price Range: Industrial-grade: RMB 12,800–13,500/ton; Pharmaceutical-grade: RMB 15,000–16,000/ton.
- Key Drivers: Peak-season baijiu demand, structurally resilient pharmaceutical-grade demand, and moderate raw material cost inflation.

2. Medium-to-Long-Term Outlook (2027)
- Price Range: Industrial-grade: RMB 12,000–13,000/ton; Pharmaceutical-grade: RMB 14,000–15,000/ton.
- Key Drivers: Emerging overcapacity risks, cost reductions enabled by technological iteration, and sustained growth in emerging application sectors.

3. Key Risks
- Intensified environmental inspections may trigger shutdowns among SMEs, potentially causing localized supply shortages.
- Widespread adoption of biocatalytic synthesis (>80% penetration) will further erode market share for traditional chemical synthesis, accelerating industry consolidation.

4. Strategic Opportunities
- Accelerated global biopharmaceutical supply chain relocation to China is expected to lift export share from 65% to 70%, with services to multinational pharmaceutical pipelines expanding to 60%.
- Growing demand from specialty polymer sectors—including PHA—offers durable incremental demand for industrial-grade ethyl butyrate.